But in September, the U.S. Food and Drug Administration banned imports of drugs from another
Ranbaxy plant that had not been implicated in the recent settlement.
Frighteningly, the problems with Ranbaxy are not isolated incidents. Over the past six years, my research group has sampled thousands of medicines used to treat tuberculosis, malaria, and major bacterial infections in emerging markets. Of these medicines, 3,695 were allegedly made by Indian companies.